Cargando…
1730. Increasing Vaccination Rates of 23-valent Pneumococcal Polysaccharide Vaccine Among Patients at High-Risk for Invasive Pneumococcal Disease
BACKGROUND: Pneumococcal disease causes significant morbidity and mortality in children. Routine childhood immunizations protect for 13 or 15 pneumococcal serotypes via two pneumococcal conjugated vaccines. Patients with immunocompromising and chronic medical conditions are at high risk of invasive...
Autores principales: | Lyon, Edward, Wetzel, Tracey, Wirtz, Ann, Swanson, Doug, Moran, Rachel R, Peters, Jessica, Symes, Christine A, Olarte, Liset, El Feghaly, Rana E |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678018/ http://dx.doi.org/10.1093/ofid/ofad500.1562 |
Ejemplares similares
-
Effectiveness of 23-valent pneumococcal polysaccharide vaccine on diabetic elderly
por: Kuo, Chia-Sheng, et al.
Publicado: (2016) -
Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults
por: Shiramoto, Masanari, et al.
Publicado: (2015) -
Effect of 23-valent pneumococcal polysaccharide vaccine on medical expenses in Japan
por: Satomura, Kazunari, et al.
Publicado: (2014) -
Comparison of immunogenicity and safety of an influenza vaccine administered concomitantly with a 13-valent pneumococcal conjugate vaccine or 23-valent polysaccharide pneumococcal vaccine in the elderly
por: Seo, Yu Bin, et al.
Publicado: (2017) -
Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)